L3VLUP
ProSign in

MMM · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MMMLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MMM
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMMMLLY
Q3 202022 holders, $4.1bn33 holders, $14.1bn
Q4 202020 holders, $4.3bn29 holders, $17.3bn
Q1 202116 holders, $4.6bn24 holders, $23.0bn
Q2 202115 holders, $5.1bn24 holders, $27.8bn
Q3 202117 holders, $4.0bn31 holders, $29.9bn
Q4 202117 holders, $3.6bn31 holders, $34.7bn
Q1 202218 holders, $2.2bn24 holders, $35.3bn
Q2 202221 holders, $2.0bn33 holders, $42.7bn
Q3 202226 holders, $2.2bn31 holders, $43.4bn
Q4 202222 holders, $2.1bn31 holders, $46.6bn
Q1 202321 holders, $1.8bn33 holders, $44.3bn
Q2 202321 holders, $1.8bn37 holders, $59.6bn
Q3 202323 holders, $1.8bn44 holders, $67.6bn
Q4 202327 holders, $2.5bn45 holders, $73.6bn
Q1 202429 holders, $3.3bn41 holders, $95.3bn
Q2 202430 holders, $4.8bn43 holders, $110bn
Q3 202434 holders, $5.9bn45 holders, $107bn
Q4 202433 holders, $5.8bn46 holders, $93.9bn
Q1 202526 holders, $7.2bn42 holders, $98.4bn
Q2 202521 holders, $6.9bn43 holders, $93.2bn
Q3 202524 holders, $6.8bn39 holders, $86.7bn
Q4 202520 holders, $6.6bn41 holders, $123bn
Q1 202626 holders, $7.0bn39 holders, $106bn
Q2 202631 holders, $7.1bn44 holders, $132bn
MMM

3M Co

Holders
33
Reported value
$5.8bn
Buyers
13
Sellers
19

Breadth -6 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
46
Reported value
$93.9bn
Buyers
24
Sellers
23

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 55 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MMM (9)

ARK Investment Management LLC, Arrowstreet Capital LP, D1 Capital Partners LP, Davidson Kempner Capital Management LP, ExodusPoint Capital Management LP, Markel Group Inc, Moore Capital Management LP, Point72 Asset Management LP, Walleye Capital LLC

Only LLY (22)

Artisan Partners LP, Bridgewater Associates LP, Capital Research Global Investors, Coatue Management LLC, D. E. Shaw & Co., Egerton Capital UK LLP, GAMCO Investors Inc, Jane Street Group LLC, Lone Pine Capital LLC, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Polen Capital Management LLC, Quantbot Technologies LP, Rokos Capital Management LLP, Soros Fund Management LLC, Susquehanna International Group LLP, Tiger Global Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →